Safety Pharmacology

The development of new medicines is a long and expensive process. Despite growing efforts in R&D over the last decades, attrition rate due to safety (especially cardiac toxicity) issues remains a major challenge for the pharmaceutical industry. Hence, safety assessment is of crucial importance during non-clinical drug evaluation. When you work with Biotrial, you are partnering with a team of non-clinical scientists holding extensive expertise in drug safety and working in state-of-the-art laboratory facilities. High quality is not just our promise; it’s our passion.

Learn more about the safety pharmacology models we offer below, or contact us to design something new.

Animal Models for Early Safety De-Risking

  • Anaesthetised and telemetered guinea pig
  • Rapid screening format for early detection of QT prolongation and other CV issues

Core Battery


  • Irwin Test / Functional Observational Battery
    • Rodents and large animals
    • We can adapt the test to your in-house protocol
  • Motor co-ordination
    • Rota-rod in rat and mouse
  • Convulsion threshold
    • Intravenous PTZ test


  • Anaesthetised and Telemetry models.
  • Rodents and large animals
  • Multi-frequency telemetry recording in pair-housed animals
  • High quality ECG in chronically-instrumented animals


  • Whole-body plethysmography in mouse, rat and guinea pig
    (IV route of administration possible).

Follow-up Studies


  • EEG telemetry in freely moving animals
    • Drug-induced change in sleep macrostructure
    • Seizure liabilities
  • Abuse Liabilities 
    • Conditioned Place Preference
    • Spontaneous Withdrawal Syndrome

  • Memory performance
    • Novel Object Recognition
    • Morris Water-Maze
    • Passive Avoidance

Tailor-made model development

Supplemental Studies

  • Gastrointestinal System 
    • Gastric emptying
    • Gastrointestinal motility
  • Renal System
    • Diuresis
    • Electrolytes excretion
    • Creatinine Clearance

Orthostatic hypotension in telemetered animals (‘tilt test’)


  • Troponin I
    • Correlation with extent of cardiac lesions
  • Kidney Toxicity
    • Panel of biomarkers providing early indication of toxicity.


For more information please contact us.


Scientific Communications